Received May 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
No additional adverse event (AE)); HCP calling to inquire about a patient who received the first GARDASIL 9 vaccine in 2017 and presents now for a second dose; This spontaneous report was received from a pharmacist and refers to a 24-year-old female patient. The patient's medical history, concurrent conditions, concomitant therapies, previous drug reactions and allergies were not reported. On an unknown date in 2017, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) injection, administered as prophylaxis (Lot No., expiration date, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided). It was stated that the patient presented now (on an unknown day in April 2025) for a second dose of the previous mention vaccine (inappropriate schedule of product administration). No additional adverse event was reported (No adverse event).